[hCG]) (2) spurred clinical trials in which administration of hCG to patients with KS yielded some promising (3, 4) but variable [(5) and references contained therein] results. Currently, the therapeutically active material is thought to be a contaminant of native hCG (6) (7) (8) , yet the nature of the contaminant remains unidentified and controversial. The reported association of anti-KS activity with a degradation product of hCG, the ␤-core (9) , or an hCG-associated ribonuclease (RNase), i.e., eosinophilderived neurotoxin (EDN) (10) , has been challenged (11) . Two contaminating hCG-associated factors, ranging in size from 2 to 4 kilodaltons (kDa) and from 15 to 30 kDa, were shown to exhibit anti-human immunodeficiency virus (HIV 1), antisimian immunodeficiency virus, and anti-KS activities (11) , but the chemical nature of the contaminants was not identified.
To circumvent the problems associated with purifying small amounts of protein contaminants with anti-KS activity from hCG or human urine, we have genetically engineered, cloned, and expressed a form of the human RNase EDN (hEDN) that contains a post-translationally processed segment of the EDN signal peptide [see also (12) ]. In this study, we have evaluated the effects of this recombinant form of hEDN, (-4)rhEDN, on the viability of KS cells and cells from a variety of other human cancers.
MATERIALS AND METHODS

Construction of a Synthetic Gene Encoding (-4)rhEDN
A 5Ј oligonucleotide was designed to incorporate the amino acids serine, leucine, histidine, and valine (SLHV) into positions -4 to -1 in relationship to the first amino acid (lysine, K) of recombinant hEDN (rhEDN) (13) .
The nucleotide sequence of the 5Ј oligonucleotide was as follows: 5Ј-ATATA-TCTAGA-AATAATTTTGTTTAACTTTAAGAAGGAGATATACAT-ATG-TCACTCCATGTC-AAACCGCCGCAGTTCACTTGG-3Ј. The first five base pairs (bp) provide a 5Ј-end clamp for later restriction enzyme digestion, the bp in bold encode an XbaI restriction site, the italicized sequence is a modified cloning vector sequence, the underlined ATG is the initiating methionine sequence, the underlined sequence in bold encodes the SLHV amino acids, and the underlined italicized sequence encodes the first seven amino acids of rhEDN.
The nucleotide sequence of the 3Ј primer, in the 5Ј to 3Ј orientation, was as follows: 5Ј-GTTCATCTGGACCGTATCATC-TAGTAG-GGATCC-GCGCG-3Ј. The first 21 bp of this 3Ј primer encode the last seven amino acids of rhEDN, the italicized sequence encodes two stop signals, the bold italicized sequence is a BamHI restriction site, and the bold sequence provides a clamp for later restriction enzyme digestion. The amino acids SLHV were attached to a synthetic rhEDN gene by use of the polymerase chain reaction (PCR), using the following cycle protocol: 94°C, 1 minute; 55°C, 2 minutes; and 72°C, 2 minutes for 20 cycles. A PCR product of the correct size was recovered from the reaction mixture by use of Gene Clean II (Bio 101 Inc., La Jolla, CA); it was digested with the appropriate restriction enzymes and cloned into the bacterial expression vector, pET-11d (Novagen, Inc., Madison, WI). The composition of the resulting synthetic gene was confirmed by dideoxynucleotide chainterminating sequencing of double-stranded DNA templates by use of a Sequenase II kit (United States Biochemical Corp., Cleveland, OH).
Protein Expression and Purification
The recombinant protein was isolated from Esherichia coli (BL21[DE3], Novagen) inclusion bodies, denatured, renatured, and dialyzed as described previously (14) before being applied to a heparin-Sepharose (Pharmacia, Piscataway, NJ) column (80 mg protein/mL resin). The protein was eluted from the column with a 0-1.0 M NaCl gradient in a buffer containing 20 mM Tris-HCl (pH 7.5) and 10% glycerol. Fractions containing (-4)rhEDN were pooled and applied to a Sephadex G-100 (Pharmacia) column (15 mm × 45 cm) that was equilibrated and eluted with a buffer containing 20 mM Tris-HCl (pH 7.5), 10% glycerol, and 0.1 M NaCl. All procedures were performed at 4°C. Native onconase and antionconase antibodies were prepared as described previously (14) . partially purified by heparin-Sepharose chromatography, or recombinant hCG (rhCG) (Sigma Chemical Co., St. Louis, MO) were made in a sterile dilution buffer consisting of 0.5 mg/mL human serum albumin in sterile H 2 O and applied (10-L volumes) to the appropriate wells. The plates were incubated at 37°C in a humidified, 5% CO 2 incubator for 3 days. A colorimetric assay, based on cleavage of the tetrazolium salt WST-1 (Boehringer Mannheim Biochemicals, Indianapolis, IN) to a soluble formazan salt, was used to determine cell viability, following the manufacturer's instructions. WST-1 (10 L) was added directly to each well. The plates were incubated for a further 30-60 minutes as described above, and the absorbance at 460 nm was determined in a microtiter plate reader (MR4000; Dynatech Laboratories, Chantilly, VA). The results are expressed as a percentage of the results obtained from buffer-treated cells.
In Vitro Analysis of Cytotoxicity
In Vitro Translation Assay and RNase Inhibitor Interaction
In vitro translation (14) and RNase inhibition (16) in the in vitro translation lysate were performed as described previously.
RESULTS
A commercial preparation of urinary hCG was tested for the presence of RNases by western blot analysis (Fig. 1) . AntirhEDN polyclonal antibodies reacted with an 18-kDa species in this preparation (Fig. 1, lane 2) . It is interesting that antibodies raised against two other recombinant human RNases, rhPanc (pancreatic ribonuclease) and rhAng (angiogenin), as well as a native amphibian RNase, Onc (onconase), did not cross-react with any proteins, indicating that this source of hCG contained an EDN-like RNase. Removal of the EDN-immunoreactive Western blot analysis of a cytotoxic preparation of urinary human chorionic gonadotropin (hCG). The hCG was subjected to electrophoresis in four separate lanes on a sodium dodecyl sulfate (0.1%)-polyacrylamide (4%-20% gradient) gel and transferred to a nitrocellulose membrane. The membrane was separated into four strips and analyzed for the presence of different ribonucleases, with the use of polyclonal antibodies that recognize rhEDN [recombinant human eosinophil-derived neurotoxin (13) 1, 3, 5 , and 7; hCG (6 g, CG-10; Sigma Chemical Co.) was applied to lanes 2, 4, 6, and 8. Mr ‫ס‬ relative molecular mass.
Fig. 2. A)
Western blot analysis of urinary human chorionic gonadotropin (hCG) before and after heparin-Sepharose chromatography. hCG (CG-10, 0.8 mg protein in 0.8 mL; Sigma Chemical Co.) was applied to a 0.5-mL heparinSepharose column (precentrifuged gently to remove buffer without destroying the beads), and the column was centrifuged to collect all protein that did not adhere to the resin; 67% of the applied 280-nm-absorbing material did not adhere to the column. RNase by heparin-Sepharose affinity chromatography ( Fig. 2,  A ; lane 2) decreased the cytotoxicity of hCG to KS Y-1 cells (Fig. 2, B) . At the highest concentration of hCG tested (100 g/mL), approximately 80% of the KS Y-1 cells were killed compared with approximately 35% killing with the heparinSepharose-depleted preparation. Moreover, rhCG was not cytotoxic to KS Y-1 cells, and it did not contain polypeptides immunoreactive with anti-rhEDN antibodies on western blot analysis (data not shown). These results are consistent with the report of Griffiths et al. (10) that an 18-kDa RNase purified from a commercial hCG preparation is cytotoxic to KS Y-1 cells and contributes substantially to the anti-KS activity of hCG.
To investigate the anti-KS activity of the EDN-like RNase further-without interference from other hCG-associated factors-we assayed purified recombinant protein for anti-KS activity. In the first experiment, 100 g of urinary hCG (CG-10) decreased KS Y-1 cell viability to approximately 30% of that of mock-treated control cultures, whereas 100 g of purified rhEDN decreased cell viability to only approximately 76% of that of mocktreated controls (data not shown). Since anti-KS activity is reported to be due to contaminants in hCG (11) that might also include a urinary RNase, i.e., hEDN (10), the poor activity observed with purified rhEDN compared with the hCG preparation was puzzling, especially in view of our results showing a relationship between the amount of an immunoreactive EDN-like protein in hCG and hCG's in vitro anti-KS activity (Fig. 2) . To resolve these seemingly conflicting results, we noted the work of Sakakibara et al. (12) , who previously isolated several RNases from a partially purified preparation of hCG, including an apparent high M r (relative molecular mass) form of hEDN (34-37 kDa). That heavily glycosylated human RNase contained an extended aminoterminus derived from the hEDN signal peptide during a presumed posttranslational processing event. The amino-terminus of some RNases is important for expression of their cytotoxic properties (14, 17, 18) . Even a single amino acid substitution at the aminoterminus can markedly affect the cytotoxic properties of pancreatic-type RNases (14) . Thus, a recombinant version of hEDN that contained an aminoterminus extended by four amino acids [(-4)rhEDN, M r ‫ס‬ 16 kDa; see ''Materials and Methods'' section] was created by PCR. The sequence at the amino-terminus was confirmed by sequence analysis and is shown in Fig. 3 , A, in comparison with the sequence of rhEDN. (-4)rhEDN was purified to homogeneity (data not shown) and tested for cytotoxicity on human tumor cell lines. Although (-4)rhEDN effectively inhibited the viability of KS Y-1 cells, with an IC 50 (50% inhibition concentration) of about 6 g/mL (Fig. 3, B ) , rhEDN displayed very little activity, 3 /well; 96-well plate) were incubated with the recombinant ribonucleases (RNases), and viability was determined by use of the WST-1 tetrazolium reagent as described in the ''Materials and Methods'' section. C) Inhibition of RNase activity by the RNase inhibitor PRI (placental RNase inhibitor) in the rabbit reticulocyte lysate in vitro translation system. rhEDN or (-4)rhEDN was added to a lysate mixture containing Brome Mosaic Virus messenger RNA and [
35 S]methionine. Protein synthesis was determined in the presence and absence of PRI by measuring incorporation of label into newly synthesized proteins, as described previously (14) . Data from three experiments were pooled. Error bars represent the standard deviations. (Fig. 3, B) .
Mammalian cells contain varying levels of a cytosolic RNase A inhibitor (placental RNase inhibitor [PRI] ) that could potentially inhibit the intracellular cytotoxicity of these proteins. Differential sensitivity to PRI does not account for the differential cytotoxicity of (-4)rhEDN and rhEDN to KS Y-1 cells. Both forms of RNase equally inhibited cell-free protein synthesis, and both were sensitive to PRI (Fig. 3, C ) .
DISCUSSION
RNases are receiving renewed attention because of newly discovered activities and applications (19) . Particularly relevant to the results presented here are studies showing that nontoxic mammalian and human RNases, such as EDN, acquire specific cytotoxic activity when targeted to cancer cells by use of antibodies [(20) and references contained therein]. Thus, there is precedence supporting the hypothesis that a recognition motif that effectively targets EDN to KS cells could cause it to acquire cytotoxic properties. In this regard, a naturally occurring variant of hEDN that contains amino acid residues -4 to -1 of the hEDN signal peptide was previously purified from a preparation of urinary hCG (12) . When the sequence (SLHV) of the extension to the amino-terminus of rhEDN is expanded to include the positively charged amino acid residue lysine (K) in the +1 position of rhEDN, the resulting sequence (SLHVK) resembles that of a peptide reported to recognize KS tumors in vivo (SLVR) (21) . Moreover, small peptides can indeed target drugs, since peptides containing other recognition motifs have effectively targeted doxorubicin to tumors in vivo (21) . Since rhEDN and its variant equally inhibited cell-free protein synthesis and were equally sensitive to a cytosolic RNase inhibitor, the four amino acid extension could have altered binding, internalization, or translocation of hEDN in KS Y-1 cells. This would be consistent with the presence of a recognition motif within the amino-terminal amino acid region of the EDN variant. Antibodies specific for the amino-terminal extension will be raised to help define the mechanism by which the peptide alters the effects of hEDN on KS cells. Whether (-4)rhEDN is similar to the urinary RNase that was reported by Griffiths et al. (10) to kill KS Y-1 cells but not HeLa cells remains to be determined. In our studies, (-4)rhEDN was also only cytotoxic to KS Y-1 cells in comparison with cells from four other human carcinoma types. What is apparent from this work and from another study (11) is that rhEDN does not have marked anti-KS activity in vitro (herein) or in vivo (11) .
For the first time since the attribution of hCG-associated anti-KS activity to a contaminant(s) associated with the hormone (7, (9) (10) (11) , the activity can now be assigned a definitive molecular structure because the recombinant protein is free of any contaminants associated with hCG, fragments of hCG, or human urine. The native human protein was initially purified from hCG as a high-M r derivative (34-37 kDa) of (-4)hEDN (12) . However, after deglycosylation, (-4)hEDN was reported to have an M r of approximately 18 kDa. It is known that multiple hEDN species can be derived by different degrees of glycosylation [(22) and references therein]. It is interesting that this naturally occurring variant of hEDN is found in the urine of pregnant women; only trace amounts are found in the urine of nonpregnant women or men (22) . The apparent sex-dependent, physiologically specific distribution of the natural RNase, its association with human urinary hCG, and its cytotoxicity toward neoplastic cells derived from patients with AIDS-associated KS (15) make it a plausible candidate to be one of the factors originally proposed to influence the sexual dimorphism of KS (2), yet our results clearly show that removal of immunoreactive hEDN accounts for only part (approximately half) of the cytotoxicity of hCG to KS Y-1 cells. In fact, two studies (7, 11) demonstrate that low-M r agents (2-4 kDa) also exhibit anti-KS activity, indicating that other hCG-associated factors that have anti-KS activity remain to be identified.
In conclusion, that human RNase-based targeted therapeutics have potential for the treatment of cancer (23), coupled with the observation that intracellular hEDN has anti-HIV 1 activity (24) , implies that the unique rhEDN described herein can be explored as a new treatment option for KS.
